Verteporfin photodynamic therapy (vPDT) is a selective vaso-occlusive treatment that targets choroidal vascular abnormalities. It was initially developed to treat neovascular age-related macular degeneration using the 'standard' vPDT protocol (verteporfin 6 mg/ m ). This paper reviews the current role of vPDT therapy in the treatment of chorioretinal conditions.
Introduction
Photodynamic therapy (PDT) is a therapeutic technique involving the use of a photosensitising agent that produces selective tissue damage when activated by light of a specific wavelength.
PDT was initially developed to treat cancer by selective destruction of tumour cells and/or tumour vasculature. 1, 2 The development of improved photosensitising agents in the 1980s enabled effective PDT therapy for a variety of tumours with minimal adverse effects (notably reduced skin phototoxicity). PDT is currently approved in oncology as a topical therapy for non-melanoma skin cancer (aminolevulinic acid or methyl aminolevulinate) and as a systemic therapy for non-small cell lung cancer and oesophageal cancer (porfimer sodium) and advanced head and neck squamous cell cancer (temoporfin). 3 Ophthalmic PDT was developed in the 1990s as a treatment for subfoveal choroidal neovascularisation (CNV) in age-related macular degeneration (AMD). Encouraging results in animal models of CNV led to human clinical trials for three photosensitising agents: benzoporphyrin derivative (verteporfin), tin ethyl etiopurpurin (purlytin) and lutetium texaphyrin (Lu-tex). 4 Verteporfin emerged as the optimal agent because of its absorption spectrum, lipophilic characteristics and short serum half-life (minimising the duration of skin photosensitivity). 5, 6 This review will cover the current role of verteporfin PDT (vPDT) therapy in the treatment of chorioretinal conditions.
Mechanism of action
vPDT therapy produces selective vascular occlusion by targeting vascular endothelial cells. Verteporfin was developed to preferentially accumulate in abnormal neovascular endothelial cells through their increased expression of low-density lipoprotein (LDL) receptors compared to normal choroidal and retinal vessels. 7 Verteporfin is administered as a liposomal formulation, which may further enhance its relative selectivity for abnormal neovascularisation.
Verteporfin produces a photochemical reaction when activated by light corresponding to its absorption spectrum. Verteporfin has a broad absorption spectrum, but only the far-red peak at 689 nm is utilised in clinical practice. The use of far-red wavelength light allows good penetration through melanin, blood and fibrotic tissue enabling effective treatment of pigmented or haemorrhagic lesions located within the choroid. 8 The vPDT laser delivery system provides localised light irradiation of the target lesion.
The photochemical reaction is complex, depending on the local tissue microenvironment. Following light irradiation, verteporfin is excited from its ground state to a higher energy state. This activated verteporfin molecule interacts with oxygen and/or biological substrates, leading to the creation of cytotoxic singlet oxygen and free radicals. These highly reactive species have a very short diffusion pathway enabling localised cell damage and death. vPDT therapy produces vascular endothelial cell damage that leads to platelet aggregation, activation of the clotting cascade and microvascular occlusion. 8 The efficacy and selectivity of vPDT therapy for choroidal vascular lesions is dependent on several factors: verteporfin dosage, duration of verteporfin infusion and light dose delivered. 8, 9 Phase I/II clinical studies in neovascular AMD demonstrated that the minimum effective light dose is greater than 25 J/cm 2 and the maximum tolerated light dose (defined by retinal vessel closure) is less than 150 J/cm 2 . 5 Tissue selectivity can also be influenced by the time interval between verteporfin administration and light irradiation. 9 The timing of light irradiation should be selected so that verteporfin is at its maximal concentration in the target tissue compared to surrounding normal tissue.
vPDT treatment protocols
vPDT is a two-step procedure that involves intravenous infusion of verteporfin followed by application of 689-nm red laser light to the target lesion. The following 'standard' vPDT protocol was developed for the TAP and VIP studies to treat neovascular AMD with subfoveal CNV. 10, 11 Verteporfin is administered by intravenous infusion over 10 min at a dose of 6 mg/m 2 body surface area (BSA). A short wait of 5 min is allowed for selective localisation of verteporfin in the target lesion and clearance of drug from surrounding normal tissue. Verteporfin is then activated by exposure to low-energy (non-thermal) laser light. vPDT lasers deliver red light at a wavelength of 689 nm. The following laser parameters are used for the standard vPDT protocol: fluence 50 J/cm 2 , irradiance 600 mW/cm 2 , duration 83 s. The vPDT laser delivery system produces a circular spot of light. A slit-lamp biomicroscope is used to visualise the fundus with a standard laser contact lens. The diameter of the laser spot can be varied according to the size of the target lesion (determined by angiography). The laser spot is adjusted to exceed the greatest linear dimension (GLD) of the target lesion (typically by a margin of 500 μm). The maximum laser spot size generated by most vPDT laser delivery systems is around 7000 μm.
vPDT therapy has a good safety profile. No serious safety concerns were identified during the TAP and VIP studies. 10, 11 The most frequent adverse events are visual disturbances (10-15%), photosensitivity reactions (3%), and back pain during the verteporfin infusion (2%). Extravasation of verteporfin is the most serious complication as it can lead to severe skin necrosis if not properly treated. Following vPDT therapy, all patients should be advised to avoid exposure to sunlight for 48 h because of skin photosensitivity.
Various protocols have been developed in order to enhance the efficacy and safety profile of vPDT therapy. These vPDT protocol variations are based on the doseresponse-dependent nature of the photochemical reaction. The most widely used 'safety-enhanced' vPDT protocols utilise reduced dose verteporfin (typically verteporfin 3 mg/m 2 BSA) or reduced fluence vPDT (typically vPDT laser fluence 25 J/cm 2 ). There is limited evidence to determine the optimum vPDT therapy parameters for different chorioretinal conditions. [12] [13] [14] [15] Neovascular age-related macular degeneration vPDT therapy was developed to treat neovascular AMD with subfoveal CNV. Phase I/II clinical studies demonstrated that a single treatment achieved effective CNV closure, but reperfusion typically occurred after 6-12 weeks. 5 Multiple applications of vPDT enabled longer term CNV control without significantly increased adverse effects. 6 This strategy was adopted in randomised clinical trials to investigate the efficacy of vPDT therapy for neovascular AMD.
The TAP study (published 2001) demonstrated that vPDT therapy was a moderately effective treatment for predominantly classic CNV lesions. 10 It significantly reduced the risk of moderate and severe visual loss in this group of patients for at least 2 years. The VIP study (published 2001) demonstrated that vPDT therapy provided marginal benefit in the treatment of occult CNV lesions (with recent disease progression). 11 Subgroup analysis suggested a greater benefit for relatively small lesions or larger lesions with relatively poor visual acuity. The VIM study (published 2005) demonstrated a marginal benefit for vPDT therapy in the treatment of relatively small minimally classic CNV lesions. 12 The standard vPDT therapy protocol was established by the TAP and VIP studies. Following baseline vPDT treatment, patients are reviewed every 3 months with repeat vPDT treatment if the CNV lesion reactivates as judged by leakage on fluorescein angiography. Repeat vPDT treatments are applied using a laser spot size corresponding to the recurrent area of leakage (plus a margin of 500 μm). This follow-up process is continued indefinitely until the CNV lesion has stabilised (ie inactive CNV lesion with minimal fluorescein leakage and stable visual acuity). Most patients experience some visual deterioration during their course of vPDT therapy, which usually occurs during the first 12 months.
The treatment of neovascular AMD underwent a paradigm shift following the MARINA and ANCHOR studies (published 2006). [16] [17] [18] Anti-VEGF therapy with ranibizumab was demonstrated to be an effective treatment for all types of subfoveal CNV lesion. This treatment modality stabilised vision in most patients and, furthermore, improved vision in~30% of patients. Anti-VEGF therapy was rapidly adopted as the standard of care for neovascular AMD since it was much more effective than vPDT therapy.
There has been some interest in combination therapy using ranibizumab and vPDT to treat neovascular AMD. Combining treatment modalities with differing mechanisms of action may have synergistic effects, thereby leading to improved outcomes. It was proposed that vPDT might reduce the frequency of ranibizumab injections, which represents a significant treatment burden with anti-VEGF monotherapy. Unfortunately, combination therapy was found to provide no significant benefit in the MONT BLANC and DENALI studies (published 2012). 19, 20 The RADICAL study also found no significant benefit from triple therapy using vPDT, ranibizumab, and dexamethasone (ClinicalTrials.gov Identifier NCT00492284, September 2015).
Currently, there is a very limited role for vPDT therapy in the treatment of neovascular AMD. vPDT therapy can be used as rescue therapy in patients not responding to anti-VEGF monotherapy. 21 It is, however, also important to consider alternative diagnoses in anti-VEGF non-responders (in particular chronic central serous chorioretinopathy or polypoidal choroidal vasculopathy), which might respond to different treatment modalities such as vPDT. vPDT therapy can occasionally be useful to treat patients unable to tolerate the intravitreal injection procedure required for anti-VEGF therapy. When treating neovascular AMD, reduced fluence vPDT (25 J/cm 2 ) may possibly reduce the risk of treatment-related visual loss compared with standard fluence vPDT (50 J/cm 2 ). 12 Non-AMD choroidal neovascularisation vPDT therapy has also been investigated for the treatment of non-AMD causes of subfoveal CNV such as pathological myopia, angioid streaks, presumed ocular histoplasmosis syndrome, and idiopathic CNV. 22 The VIP study investigated the safety and efficacy of vPDT therapy for myopic CNV. It reported a significantly better visual outcome at 12 months, 23 but no significant visual benefit at 24 months. 24 The failure to demonstrate long-term efficacy is probably due to vPDT-related chorioretinal atrophy in a condition that tends to regress spontaneously. A longer term study did suggest some benefit in patients with better initial visual acuity and larger lesions in younger patients. 25 More recent clinical trials have, however, demonstrated that anti-VEGF therapy achieves much better visual outcomes for myopic CNV than vPDT therapy. [26] [27] [28] Anti-VEGF therapy is currently the standard of care for treating myopic CNV. 29 vPDT therapy has been used as a treatment for other causes of CNV with variable outcomes. Guidelines were published at an early stage based on the clinical trial experience of vPDT therapy for neovascular AMD and myopic CNV. 30 The evidence base for vPDT therapy in other causes of CNV has necessarily been developed from published case reports and small case series. It is not feasible to conduct clinical trials owing to the infrequent occurrence of these conditions. In more recent years, anti-VEGF therapy has largely replaced vPDT therapy as the preferred treatment modality for these other causes of CNV as it achieves much better visual outcomes (similar to the situation with myopic CNV). 31, 32 Choroidal haemangioma Choroidal haemangiomas require treatment when vision is affected by macular oedema or exudative retinal detachment. Asymptomatic lesions can be safely observed since there is a low risk of progression with visual deterioration. Various techniques have been used to treat choroidal haemangiomas in the past including laser photocoagulation, transpupillary thermotherapy, and radiation therapy (external beam, plaque brachytherapy, or proton beam). vPDT therapy is now considered to be the treatment of choice for this condition.
In many respects, choroidal haemangioma can be regarded as a prototypic disease for vPDT therapy owing to the characteristics of its vascular structure. Verteporfin is sequestered in the abnormal large calibre vessels with limited accumulation in normal choriocapillaris. vPDT therapy therefore enables selective targeting of the tumour vessels with minimal damage to the overlying neurosensory retina. Multiple case series have been reported demonstrating that vPDT therapy achieves high rates of tumour control with minimal complications. [33] [34] [35] [36] [37] [38] Choroidal haemangiomas can be effectively treated using the standard vPDT protocol-verteporfin dosage 6 mg/m 2 BSA and vPDT laser fluence 50 J/cm 2 (600 mW/cm 2 for 83 s). 36, 37 Alternative vPDT protocols have been reported, generally involving a higher vPDT laser fluence of 100 J/cm 2 (600 mW/cm 2 for 166 s). [33] [34] [35] 38 The maximum laser spot size generated by most vPDT laser systems is around 7000 μm. Consequently, treatment of larger choroidal haemangiomas may require multiple, partially overlapping laser spots (administered during the same treatment session).
The majority of patients with choroidal haemangioma require only one vPDT treatment session in order to achieve long term tumour control (Figure 1 a.1-a.5) . The end point of treatment is generally considered to be elimination of exudation rather than complete tumour regression. There is usually some reduction in tumour thickness following vPDT therapy. Complete tumour regression generally requires more aggressive vPDT therapy with a potential risk of adverse effects such as choroidal atrophy and neurosensory retinal degeneration. 33 Radiation therapy remains a useful treatment modality for larger choroidal haemangiomas with extensive exudative retinal detachment that are not amenable to vPDT therapy. 39 There is, however, a risk of radiationinduced complications (cataract, radiation retinopathy and optic neuropathy). Diffuse choroidal haemangiomas associated with Sturge-Weber syndrome can be treated by vPDT therapy, 40 though radiation therapy may be required for more severe cases.
Central serous chorioretinopathy
Central serous chorioretinopathy (CSC) is an idiopathic chorioretinal condition. The aetiology is incompletely understood but a principal feature is localised choroidal vascular hyperpermeability. Breakdown of the retinal pigment epithelial (RPE) barrier leads to leakage of fluid into the subretinal space with development of a macular neurosensory detachment. CSC can be broadly classified into two types based on clinical characteristics. 41 Acute CSC tends to affect younger individuals with spontaneous resolution typically occurring within 3 months. Chronic or recurrent CSC tends to affect older individuals with a less favourable visual outcome. Progressive visual loss may develop due to foveal attenuation, cystoid macular degeneration, or damage to the foveal photoreceptor layer. Foveal photoreceptor atrophy can develop as early as 4 months after onset of symptoms.
CSC is initially managed conservatively as most cases will resolve spontaneously with visual recovery within a reasonable timeframe. In some cases, corticosteroid usage may be a contributory factor and stopping treatment should be considered (if possible). 41 Laser photocoagulation was the traditional treatment for persistent CSC, but can potentially cause significant adverse effects (symptomatic scotomas, RPE atrophy, and secondary CNV). Micropulse diode laser with subthreshold therapy may be equally effective with reduced adverse effects. 42 However, vPDT therapy is now generally considered to be the preferred treatment modality since it can directly target the principal abnormality of choroidal hyperpermeability. 43, 44 The proposed mechanism for vPDT therapy is closure of the abnormal leaking choroidal vessels with subsequent choroidal vascular remodelling. 45 vPDT therapy is generally directed at the leakage site(s) identified on fluorescein angiography (Figure 1 b.1-b.5 ). It is possible that vPDT therapy might be better guided by indocyanine green (ICG) angiography, which typically demonstrates more widespread choroidal vascular abnormalities. 46 Potential adverse effects of vPDT therapy include damage to the normal choriocapillaris and RPE leading to choroidal ischaemia, RPE atrophy and secondary CNV. These adverse effects assume greater significance when treating leakage site(s) close to the fovea.
CSC can be effectively treated using the standard vPDT protocol-verteporfin dosage 6 mg/m 2 BSA and vPDT laser fluence 50 J/cm 2 (600 mW/cm 2 for 83 s). 47 Alternative safety-enhanced vPDT protocols have been developed to provide effective treatment with reduced potential for adverse effects. Two principal approaches have been adopted as the photochemical response in the choroid is dose-response-dependent. Half-dose vPDT therapy uses a verteporfin dosage of 3 mg/m 2 BSA. 13,48-52 Reduced fluence vPDT therapy uses a vPDT laser fluence of 25 J/cm 2 (300 mW/cm 2 for 83 s). 14, 15, 53, 54 There is limited evidence to compare these different vPDT protocols for CSC in the absence of randomised controlled trials. 44, [55] [56] [57] [58] The current approach to management of CSC is largely empirical. There is good evidence that vPDT therapy is a useful treatment option, but published studies are limited by selection bias, lack of randomisation, small sample size, and short follow-up. 41, 58 Selection of patients for vPDT therapy should be guided by factors such as duration, severity of visual symptoms and location of leakage site(s) relative to the fovea. The optimum vPDT protocol in respect of efficacy and safety remains to be determined. There is a need for robust clinical trials to investigate the role of vPDT therapy in the treatment of CSC, considering both the visual outcome of the treated episode and the recurrence rate in the longer term. It is noteworthy that the FDA granted orphan drug designation to verteporfin for the treatment of chronic or recurrent CSC in September 2012, which may help to drive future research.
Polypoidal choroidal vasculopathy
Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy characterised by an inner choroidal branching vascular network (BVN) with nodular polypoidal lesions. 59 The aetiology is uncertain but arteriosclerosis of the choroidal vessels appears to be an important pathological feature. The typical clinical presentation is recurrent episodes of serous and/or haemorrhagic pigment epithelium detachment. The polyps may be visible as orange-red subretinal nodules. Diagnosis of PCV requires ICG angiography. It is defined as single or multiple focal nodular areas of hyperfluorescence arising from the choroidal circulation in the early phase (with or without visualisation of an associated BVN). 60 There is a strong racial predilection for Asians and Africans compared with Caucasians. PCV is generally considered to be a distinct clinical entity (rather than a variant of neovascular AMD).
The best approach to treatment of PCV remains uncertain. Spontaneous resolution with visual recovery can occur in some cases. 61 ICG-guided laser photocoagulation of active (leaking) polyps has been used in the past with variable success rates. 62, 63 Current methods of treatment involve the use of vPDT therapy and/or anti-VEGF therapy. ICG-guided vPDT treatment of active (leaking) polyps can resolve macular oedema through direct occlusion of polyps. [64] [65] [66] Complete polyp regression is usually achieved with 1 or 2 treatments (Figure 1 c.1-c.5 ). The main adverse event is subretinal haemorrhage, which is usually limited and resolves without significant visual deterioration. 64, 67 Anti-VEGF therapy can also be beneficial in the treatment of PCV. It can reduce macular oedema, but has a variable effect on polyp regression. 68, 69 The EVEREST study demonstrated that vPDT therapy, either alone or in combination with ranibizumab, is better than ranibizumab monotherapy. 70 Evidence-based guidelines for diagnosis and treatment of PCV have recently been developed. 60 These were based on a systematic literature review (including the EVEREST study as the only published randomised controlled trial) and expert opinion. Recommended initial treatment is ICG-guided vPDT monotherapy or combination therapy with vPDT and ranibizumab (comprising three intravitreal injections of ranibizumab 0.5 mg 1-month apart). If there is incomplete regression of polyps by ICG angiography, then further treatment should comprise vPDT monotherapy or combination therapy with vPDT and ranibizumab. If there is complete regression of polyps by ICG angiography but leakage on fluorescein angiography and other clinical or anatomical signs of disease activity, then further treatment should comprise ranibizumab.
Diagnosis (requiring ICG angiography) is probably the most important factor influencing successful treatment of PCV. A proportion of patients with clinical features suggestive of neovascular AMD will instead have PCV. The prevalence is estimated to be 5-10% among Caucasian patients and 20-50% among Asian patients. 60, 71 Further research is required to determine the optimum treatment for PCV. Current guidelines recommend the standard vPDT protocol-verteporfin dosage 6 mg/m 2 BSA and vPDT laser fluence 50 J/cm 2 (600 mW/cm 2 for 83 s). 70 There is limited evidence for using alternative safety-enhanced vPDT protocols in PCV (such as half-dose or reduced fluence vPDT). Current guidelines recommend vPDT treatment of the entire PCV lesion (polyps plus BVN) rather than only the active (leaking) polyps. 60 Further research is also required to define the role of anti-VEGF agents (to reduce leakage from polyps and the BVN) in combination therapy for PCV.
Peripapillary choroidal neovascularisation
Peripapillary CNV (PP-CNV) is defined as CNV located within one disc diameter of the optic nerve head. This condition is often idiopathic, but it can also occur secondary to inflammatory conditions (such as serpiginous choroidopathy or presumed ocular histoplasmosis syndrome) and optic nerve malformations (such as optic disc drusen or optic disc coloboma). PP-CNV becomes symptomatic owing to macular involvement from fluid exudation or haemorrhage. In some cases, the PP-CNV lesion can enlarge leading to direct foveal involvement.
Asymptomatic PP-CNV can be managed conservatively (particularly if located outside the macular arcade vessels) as spontaneous involution will often occur. Laser photocoagulation was the traditional treatment for symptomatic PP-CNV but carries a risk of thermal injury to the overlying neurosensory retina with consequent visual loss. The current treatment modalities comprise vPDT therapy or anti-VEGF therapy. 72 vPDT therapy usually achieves PP-CNV regression following 1 or 2 treatments with only a small risk of an adverse effect (Figure 1 d.1-d.5) . 73, 74 Anti-VEGF therapy is also effective but may require multiple injections to achieve PP-CNV regression. 75, 76 Most reports of vPDT therapy for PP-CNV have used the standard vPDT protocol-verteporfin dosage 6 mg/m 2 BSA and vPDT laser fluence 50 J/cm 2 (600 mW/cm 2 for 83 s). Safety-enhanced vPDT protocols (such as half-dose or reduced fluence vPDT) may be equally effective since PP-CNV lesions tend to be less aggressive than subfoveal CNV lesions. When treating neovascular AMD, it has been advocated that the vPDT laser spot should not extend closer than 200 μm to the border of the optic nerve head in order to avoid optic nerve damage. There is, however, evidence that the optic nerve head can be included in the treatment zone for PP-CNV lesions without causing optic nerve damage. 74 Conclusion vPDT therapy is a selective vaso-occlusive treatment that targets choroidal vascular abnormalities. It was initially developed to treat neovascular AMD with subfoveal CNV. The TAP and VIP studies (published 2001) demonstrated that vPDT was a moderately effective treatment for neovascular AMD with a good safety profile. vPDT therapy became the standard treatment for neovascular AMD until replaced by anti-VEGF therapy following the MARINA and ANCHOR studies (published 2006). Subsequently, vPDT therapy has evolved as an important treatment modality for a range of other chorioretinal conditions including choroidal haemangioma, central serous chorioretinopathy, polypoidal choroidal vasculopathy, and peripapillary choroidal neovascularisation. Published studies are, however, generally limited by selection bias, lack of randomisation, small sample size and short follow-up. Further research is required to optimise the vPDT protocols used to treat these chorioretinal conditions.
